Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01988987 · ClinicalTrials.gov registry record

Evaluating for Type-2 Diabetes in the Very Early Postpartum Period

A clinical trial, sponsored by NYU Langone Health.

Completed
Registry status
123
Enrollment target

NCT01988987 is a clinical trial that has completed, run by NYU Langone Health. The registered enrollment target is 123 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01988987 has completed, sponsored by NYU Langone Health.

COMPLETED
Registry status
123 participants
Enrollment target

Study Summary

Pregnancy-associated diabetes, known as gestational diabetes mellitus (GDM), is associated with an increased lifetime risk of developing diabetes mellitus (DM) or pre-diabetes. Up to 30% of women with GDM will continue have abnormal blood glucose tests 6 or more weeks after delivery. Early diagnosis and treatment of continued impaired glucose metabolism or DM is essential because serious health problems can result. Current guidelines recommend a 75-gram, 2-hour glucose tolerance test (GTT) 6 or more weeks after delivery for women diagnosed with GDM in order to identify those with continued DM or impaired glucose metabolism. However, approximately half of these women do not get glucose testing after delivery. The ability to test women while they are still hospitalized after having a baby could greatly increase diagnosis, care and treatment of women with abnormal glucose metabolism. Our objective is to determine if a 75-gram, 2-hour GTT administered to women with GDM two to four days after delivery can identify those who will have an abnormal GTT at 6-12 weeks after delivery.

Interventions

  • OTHER Inpatient Postpartum GTT

Trial Details

FieldValue
Enrollment Target 123 participants
Start Date 2013-02-22
Est. Completion 2018-11-30

Sponsor

NYU Langone Health

1,164 total trials

What the Registry Record Tells You About NCT01988987

The ClinicalTrials.gov registry entry for NCT01988987 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 123 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Inpatient Postpartum GTT is the first listed.

NCT01988987 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT01988987 about?

NCT01988987 is a clinical study titled "Evaluating for Type-2 Diabetes in the Very Early Postpartum Period". Pregnancy-associated diabetes, known as gestational diabetes mellitus (GDM), is associated with an increased lifetime risk of developing diabetes mellitus (DM) or pre-diabetes. Up to 30% of women with GDM will continue have abnormal blood glucose tests 6 or more weeks after delivery. Early diagnosis...

What is the current status of trial NCT01988987?

This trial is currently completed. The enrollment target is 123 participants. The study started on 2013-02-22. Estimated completion is 2018-11-30.

What interventions are being tested in trial NCT01988987?

The interventions under investigation include: Inpatient Postpartum GTT (OTHER).

Who is sponsoring clinical trial NCT01988987?

This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.